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ABSTRACT 
Extracts of three species of sponge and an egg mass of the nudibranch Hexabranchus 
sanguineus were examined because they displayed biological activity against either BACE1 or 
HSV-1 and VSV. In some cases bioactivity guided isolation led to the purified active agent, while 
in others a loss in activity led to chemical investigations of the extract. The fruits of this labor 
were the identification, characterization, and, in most cases, biological evaluation of 7 new and 
10 known compounds from four separate structural classes. The structures of these compounds 
were elucidated through analyses of NMR experiments (
1
H, 
13
C, TOCSY, HMBC, HSQC, 
COSY, ROESY, and NOESY), HR-MS data, computational simulations, and optical rotations. 
For reference, the structures of these compounds are on the next page. 
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CHAPTER 1 
1. Introduction1 
1.1. A Brief History of Natural Products  
For centuries, mankind has looked towards Nature for inspiration. We have used Nature’s 
chemistry to increase our effectiveness in both taking and preserving life. In warfare, tribes 
would coat their weaponry in toxins to make them more dangerous. For example, native 
Hawaiians on Maui would dip their spears in a sacred pool, rubbing the tips against the seaweed-
like soft coral, thereby coating them with the deadly toxin palytoxin.
2
 This is not an isolated 
example, as South American natives would rub the ends of their weapons on poison dart frogs, 
essentially applying lethal or paralysis-inducing alkaloids like epibatidine,
3
 to help ensure the 
kill.  
The use of Nature’s bounty as traditional medicines has flourished, as well. Almost all ancient 
civilizations used plants and herbs as a means to remedy their ailments and/or enhance other 
characteristics. Ancient Egyptians would apply honey to wounds knowing that it helped promote 
healing and prevent festering.
4
 Other cultures, such as the Incans, used plants to combat hunger 
and fatigue, unaware they were ingesting the powerful narcotic cocaine by chewing on coca 
leaves.
5
 While the use of these traditional medicines flourished, one thing was certain, most 
knew nothing about the active components these medicines contained. 
As civilizations and technology became more advanced, there was a shift from traditional 
medicines to pharmacognosy. Scientists began isolating and identifying the bioactive 
components of these traditional medicines and poisons. This work led to many well-known 
2 
 
molecules that are still used today. These were molecules like morphine,
6
 extracted from opium 
poppy, or salicin,
7
 a precursor to the drug aspirin from willow bark. During the first half of the 
1900's, the major families of antibiotics were identified including the penicillins
8
 and 
tetracyclines.
9
 The discovery of these compounds fundamentally changed modern medicine. 
With these antibiotics widely available, mortality rates gradually decreased,
10
 as influenza and 
pneumonia were no longer within the top five leading causes of death.
11
  
Buoyed by these successes, screenings campaigns were conducted using these traditional 
medicines and poisons to identify compounds that could alleviate other ailments such as 
hypertension, malaria, or cancer. This work produced many drug leads and a plethora of FDA 
approved agents such as the anticancer drugs paclitaxel,
12
 daunorubicin,
13
 and camptothecin.
14
  
Artemisinin
15
 (an antimalarial agent) and lovastatin
16
 (cholesterol lowering agent) are fruits of 
natural product chemistry that currently generate billions in revenue every year.  
Up until the 1950’s, most natural product research was conducted on terrestrial organisms. It 
was not until the advent of SCUBA that researchers began intense investigations of the marine 
environment. Being able to spend prolonged periods underwater allowed researchers to explore 
new ecological niches and collect new organisms including sponges, tunicates, mollusks, and 
marine cyanobacteria. These organisms have become extremely productive sources of new 
chemistry.
17
 Having this “new” environment to peruse has yielded seven approved marine 
drugs,
18
 e.g. the anticancer alkaloid trabectedin,
19
 isolated from a tunicate, which binds to the 
minor groove of DNA. Ziconotide,
20
 a peptide obtained from a cone snail’s poison used to treat 
severe chronic pain, is another fruit of this labor. Currently there are approximately two dozen 
marine-derived compounds in clinical trials.
 21,22
 
 According to Newman and Cragg, approximately 46% (558) of all small molecule approved 
drugs are natural products or their derivatives.
23
 This indicates that screening Nature’s creations 
3 
 
for molecular scaffolds is a viable strategy for the discovery of new leads. Given the impressive 
track-record, it is no wonder that we still look to Mother Nature to cure us.  
 
1.2. Selected Target of Current Pathology: BACE1 and Alzheimer’s Disease  
Human life expectancies are increasing, in part, due to advances in modern medicine. A 
byproduct of longer lifespans is that other pathologies which often take a longer time to develop 
begin to manifest. One such disease is Alzheimer’s disease (AD). In the United States alone, an 
estimated 5.4 million people have AD and in 2016, it was expected to have cost over $236 billion 
(not including the enormous amount of unpaid family care).
24
  
While the exact cause of AD is not known, there are several hypotheses. The two major 
hallmarks of AD are tau tangles and Aplaques located in the brain. One hypothesis being 
investigated deals with the development of tau tangles in the brain,
25,26
 which are caused by 
hyperphosphorylation of tau protein abundant in neurons of the central nervous system.
27
 When 
this hyperphosphorylation occurs, the tau proteins can self-assemble tangles, or if the protein is 
misfolded, the usually soluble protein can now become insoluble and form aggregates.
28
 These 
tangles, which occur within the neuron, are thought to be toxic to neurons by preventing 
intracellular transport of nutrients and other essential molecules throughout the cell.
29
 The jury is 
still out on whether the tau tangles are a causative function of AD, or if they are an effect.  
The Amyloid Cascade hypothesis is a second AD hypothesis that is strongly supported.
30,31,32
 
In this hypothesis, amyloid precursor protein (APP) is cleaved by the enzyme -secretase, also 
known as BACE1 (beta-amyloid cleavage enzyme one), to generate peptide fragments which 
may then be cleaved by -secretase to form 40 or 42 amino acid insoluble peptide fragments. 
These insoluble proteins then aggregate, forming A42 plaques within the brain (Figure 1.1). The 
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A42 plaques can block neuronal connections and at elevated levels become toxic to the neurons, 
leading to neuronal degeneration and overall loss of cognitive function. Therefore BACE1 and -
secretase are potential targets for the treatment of Alzheimer’s; the inhibition would lead to 
diminished levels of insoluble A proteins, preventing the formation of new plaques in the brain 
and hopefully slowing/halting the onset of Alzheimer’s disease. While -secretase is not a good 
drug target, because it plays a major role in the NOTCH signaling pathway that is important in 
cell differentiation, neuronal function, and cell-cell communication,
33
 BACE1 is a suitable target 
for the treatment of Alzheimer’s as knockout mice deficient of BACE1 don’t have any overtly 
abnormal phenotypes.
34
 The inhibition of BACE1 would lead to diminished levels of insoluble 
A proteins, preventing the formation of new plaques in the brain and hopefully slowing/halting 
the onset of Alzheimer’s disease.  
 
 Figure 1.1 Formation of Amyloid Plaques Found in AD. Cleavage of amyloid precursor protein (APP) by a-
secretase forms soluble fragments where-as cleavage by both BACE and -secretase yields insoluble 
A40/42 proteins that aggregate to form plaques. Image modified from Mattson, M. P. Nature. 2004, 430, 
631. 
 
Currently, five drugs are approved by the FDA to treat AD. However, these drugs only treat the 
cognitive symptoms, and none target the possible cause. For instance, four of the drugs are 
acetylcholinesterase inhibitors (AChEI), including galantamine, a natural product drug derived 
from the bulbs of the lily, daffodil and related plants. AChEIs works by inhibiting the hydrolysis 
5 
 
of acetylcholine, allowing for the neurotransmitter to continue activating neurons.
35
 The fifth, 
memantine, is an N-methyl D-aspartate antagonist, which works by regulating glutamate levels in 
the brain, preventing them from rising to cytotoxic levels.
36
 Since these drugs do not treat the 
cause, neurological deterioration due to AD continues, and unless a medical breakthrough 
occurs, the incidence rate of AD is expected to double in twenty years.
24
  
 
1.3. Research Objectives and Strategies 
When a new drug target arises, such as BACE1, there are typically two major approaches in 
drug discovery from nature; bioactivity guided isolation and high-throughput screening of 
libraries of pure, previously isolated compounds (Figure 1.2). In the bioactivity guided approach, 
samples are collected, extracted, and fractionated with each fraction tested in an assay for 
activity. The assay is dependent upon the researcher’s interest and goals. Any fractions that 
display activity are checked for purity by 
1
H NMR and LCMS. An impure fraction then goes 
back to the fractionation stage, being fractionated under different conditions. This could be 
anything from changing the chromatography stationary phase, the mobile phase gradient, or even 
using liquid-liquid partitionings or dialysis. The new fractions are tested again for activity and 
the active fractions checked for purity. This loop continues until a pure and active compound is 
isolated. Then the compound is characterized and its structure elucidated. As a lower priority, 
inactive fractions are then sometimes subject to fractionation in order to isolate other pure 
compounds. Usually this approach is directed by an interesting mass, 
1
H NMR, or UV 
chromatogram. The pure compounds are then screened against various assays often in a directed 
fashion based on substructures. 
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Figure 1.2 Two General Strategies for Drug Discovery. Method 1 is the path of bioactivity guided isolation is described by 
following the black arrows. The red arrows, method 2, is the path of purity guided isolation where the goal is the 
collection of pure compounds followed by screening. Method 2 either starts from the sample stage, or more commonly 
if activity is lost during method 1. 
The intent of this research was primarily the identification of new and interesting natural 
products drug leads. Focusing first on the bioactivity guided isolation of strong inhibitors of 
BACE1, sometimes subsequent purification proves the initial activity was a false positive. In 
these cases, a secondary goal was the identification of new compounds based on interesting 
1
H 
NMR, MS, or UV chromatograms and then evaluating biological activities inferred by 
knowledge of their analogues.  
Samples of marine organisms were collected from a variety of locations around the Hawaiian 
Islands. Biological samples were extracted and subjected to a crude fractionation based on 
polarity with all fractions stored in 96 well plates for easy screening and distribution to 
collaborators. Preliminary data was collected by screening these samples against BACE1 and 
projects were chosen based on their strength of inhibition. Samples displaying less than 60% 
activity and within three standard deviations of the negative control were deemed “active,” while 
samples displaying less than 40% activity were deemed “very active.”  
The BACE1 EFC assay worked as follows. A circular peptide containing both an enzyme 
donor (ED) and BACE1 cleavage site was incubated with our sample and BACE1 enzyme. After 
incubation, an enzyme acceptor reagent was added followed by the chemiluminescent substrate. 
7 
 
If BACE1 is uninhibited it will cleave the circular peptide such that the ED domain is now 
available for binding to the enzyme acceptor (EA) reagent. When ED and EA bind properly, a 
working -galactosidase enzyme is formed which can cleave the chemiluminescent substrate 
thereby producing light. This light is monitored as a proxy for activity where less light equates to 
more inhibition and therefore greater “activity.” The overall process can be seen in Figure 1.3. 
 
Figure 1.3 BACE1 EFC Assay System. Modes and points of apparent inhibition of BACE1 can be seen at the red arrows. 
Cleavage is the BACE1 cleavage site, ED is the enzyme donor, EA is the enzyme acceptor, and the lightning bolt 
represents chemiluminescence. 
Since any disruption in light will be interpreted as inhibition, it is important to note the ways 
this could happen. These ways include if the targeted enzyme BACE1 is inhibited, if the sample 
disrupts the complementation process of EA and ED, or if the resulting -galactosidase is 
inhibited. Therefore, active fractions originating from the 100% MeOH or other very lipophilic 
fractions were deemed lower priority since they are likely to disrupt the complementation 
process or form promiscuous aggregators and sequester away enzyme. Likewise, 25% MeOH 
fractions were deemed lower priority due to their typical large sugar content which is more likely 
to inhibit or compete for the -galactosidase.  
From 2010-2014 over 500 biological samples have been collected, extracted, and fractionated 
into over 3,000 samples. Each sample has been screened in the aforementioned EFC BACE1 
assay to provide about 51 very active fractions (< 40% enzyme activity; 1.6% of total samples), 
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and an additional 87 somewhat active fractions (60% to 40% enzyme activity; 2.7% of total 
samples). This is displayed in Figure 1.4A. A second way to visualize this data is by fraction 
where it becomes easier to prioritize the samples Figure 1.4B. 
A)    
B)  
Figure 1.4 EFC BACE1 Assay Screening Results. A) All fractionated samples tested are lumped into six categories based upon 
% DMSO control activity in their respective assay. Blue, red, and green bars (>60%) are considered inactive. Purple 
represents moderate activity samples (60%< >40%), while blue and orange are strong activity samples(<40%). B) Same 
data as above displayed as a scatterplot by fraction to infer polarity of the sample. From left to right the fractions in % 
MeOH are: 100, 25, 50, 75, 90, crude, iPrOH 
  
Here-in we report the results of three projects chosen based on the BACE 1 results above, and 
a fourth project based on inhibition of herpes simplex virus 1 (HSV-1) and vesicular stomatitis 
virus (VSV). In two of these cases bioactivity is lost after fractionation which resulted in the 
chemical investigation of the animal. In all cases, new secondary metabolites have been isolated, 
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their structures determined, and the compounds subjected to varying degrees of biological 
evaluation. 
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CHAPTER 2 
2. Ulapualides C-E Isolated From a Hawaiian Hexabranchus sanguineus Egg 
Mass
37
 
2.1. Overview of Hexabranchus sanguineus metabolites 
Originally isolated in 1986 from egg masses of the nudibranch Hexabranchus sanguineus, the 
ulapualides
38
 derive their Hawaiian name from the flowerlike appearance of the Spanish dancer’s 
eggs underwater (ula=red and pua=flower). The ulapualides contain a characteristic tris-oxazole 
moiety and a long aliphatic tail similar to the mycalolides
39
 and kabiramides.
40
 These compounds 
exhibit strong cytotoxicity which is proposed to protect the egg masses from predation. The 
cytotoxicity arises from the conserved aliphatic tail region that irreversibly binds to G-actin and 
behaves as a molecular mimic of the actin severing protein gelsolin.
41
 Taking advantage of this 
strong affinity allowed co-crystallization with G-actin that provided the absolute configuration of 
ulapualide A (2.1) via X-ray crystallography.
42,43
 
 As part of our ongoing search for BACE1 inhibitors, preliminary data in our BACE1 affinity 
assay suggested the ulapualides in crude extracts bound to that enzyme. After purification, 
however, ulapualides A (2.1) and B (2.2) showed no significant inhibition of BACE1 when 
tested at concentrations up to 30 μM. Further chemical investigation of the extract led to the 
isolation and identification of three new analogs, ulapualides C-E (2.3-2.5), described within.  
 
11 
 
 
Figure 2.1 Ulapualides Isolated From Hexabranchus sanguineus Egg Mass 
 
 
2.1.1. Isolation and Structure Determination Ulapualides A-E 
Two egg masses from the west shore of Oahu (Electric Beach) were extracted with 1:1 
MeOH:CH2Cl2 overnight three times. The resultant extract was dry loaded on C8 silica gel and 
subjected to a stepped gradient of MeOH:H2O. The 75% MeOH fraction was separated by 
reversed-phase HPLC leading to the isolation of ulapualides A and B (2.1-2.2), along with 
ulapualide C (2.3) and a mixture of two other analogs. Subjecting this mixture to further HPLC 
using a different eluent afforded ulapualides D (2.4) and E (2.5). 
1
H and 
13
C NMR data were 
collected on all isolated compounds (Tables 2.1 and 2.2, respectively), but insufficient sample 
was available for direct detection of 
13
C NMR for 2.4 and 2.5. Consequently, 
13
C chemical shifts 
were obtained from indirect HSQC and HMBC experiments for these two compounds.
44
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Table 2.1. 
1
H NMR Chemical Shifts of Ulapualides C-E (2.3-2.5) in CDCl3 
 
 Ulapualide C (3)  Ulapualide D (4)  Ulapualide E (5) 
position H (J in Hz)
a
 [minor]
b 
 H (J in Hz)
a
 [minor]
b 
 H (J in Hz)
a
 [minor]
b 
2 2.45, m  2.49, m   2.46, m 
3 4.23, septet (4.1)  4.17, m  4.23, septet (4.1) 
4 1.65, m 
1.55, m 
 1.72, m  1.72, m 
1.60, m  
5 1.95, m 
1.79, m 
 1.25, m  1.96, m 
1.76, m 
6 2.55, m  1.76, m 
1.41,  m 
 2.57, m 
7   4.07, br t (8.4)   
8 3.10, m 
2.51, dd (4.9, 16.3) 
 1.76, m 
1.71, m 
 3.01, m 
2.51, dd (15.5, 3.7) 
9 3.41, m  2.98, m  3.42, m 
9-Me 1.31, d (7.0)  1.32, d (7.0)  1.32, d (6.9) 
11 7.41, d (1.0)  7.40, d (1.3)  7.40, s 
14 8.06, s  8.08, s  8.06, s 
17 8.06, s  8.06, s  8.06, s 
19 6.38, d (16.0)  6.31, d (15.7)  6.39, d (16.5) 
20 7.05, dt (16.0, 7.4)  7.09, ddd  (15.3, 8.9, 6.0)  7.01, m 
21 2.66, ddt (14.4, 4.6, 1.8) 
2.44, m 
 2.70, m 
2.36, dd (14.3, 8.2)  
 2.65, br d (14.5) 
2.42, m 
22 3.41, m   3.66, t (6.1)  3.40, m 
22-OMe 3.37, s  3.38, s  3.37, s 
23 1.85, m  1.61, t (7.1)  1.81, m 
23-Me 0.91, d (7.0)  0.88, d (6.9)  0.87, d (6.9) 
24 5.24, t (8.2)  5.26, t (9.6)  5.23, m 
25 1.54, m  1.69, m 
1.41, m 
 1.49, m 
26 2.95, br d (9.4)  2.98, m   2.93, dt (8.8, 3.3) 
26-OMe 3.30, s  3.31, s   3.28, s 
27 1.71, m  1.70, m  1.72, m 
27-Me 0.832, d (6.7) [0.828, d]  0.792, d (6.7) [0.788, d]  0.83, d (6.9) [0.82, d] 
28 1.65, m 
0.90, m 
 1.70, m  
1.25, m 
 0.94, m 
29 1.25, br s  2.44, m  1.57, m 
30 3.44, m    5.10, t (7.2) 
31 1.54, m  2.77, dd (8.8, 7.3)  1.81, m 
31-Me 0.85, d (7.0) [0.84, d]  1.06, d (7.1) [1.05, d]  0.954, d (6.9) [0.947, d] 
32 4.80, td (9.8, 2.9)  5.12, dd (8.9, 3.9) [5.13 dd]  4.75 dd (10.4, 2.4) 
32’’32-
OAc 
2.16, s [2.15, s]  2.00, s [1.99, s]  2.11, s [2.10, s] 
33 2.56, m  2.48, m  2.53, m 
33-Me 1.05, d (6.8) [1.04, d]  1.04, d (7.1) [1.03, d]  1.00, d (5.9) [0.99, d] 
34 5.00, dd (14.1, 9.4)  4.98, td (13.6, 9.4)  4.96, dt (14., 9.6) 
35 6.50, d (14.3)  6.49, d (14.0)  6.50, d (14.9) 
35-NMe 3.02, s [3.06, s]  3.02, s [3.07, s]  3.02, s [3.06, s] 
35-NCHO 8.29, s [8.07, s]  8.28, s [8.07, s]  8.29, s [8.07, s] 
37     3.81, t (4.8) 
37-OMe     3.45, s 
38     3.86, br s 
      
a
500 MHz. 
b
Proton signals in brackets are for the minor rotamer.  
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Table 2.2. 
13
C NMR Chemical Shifts of Ulapualides A-E (2.1-2.5) in CDCl3 
 
 1  2  3  4  5 
position C
a,b
 type  C
a,b
  type  C
a,b
 type  C
a,c
 type  C
a,c
 type
1 172.5 C  172.5 C  172.5 C  172.6 C  172.4 C 
2 43.0 CH2  43.0 CH2  43.0 CH2  43.4 CH2  42.8 CH2 
3 68.1 CH  68.1 CH  68.0 CH  69.0 CH  68.3 CH 
4 37.1 CH2  37.1 CH2  37.1 CH2  37.5 CH2  37.0 CH2 
5 20.8 CH2  20.7 CH2  20.8 CH2  29.8 CH2  20.5 CH2 
6 43.8 CH2  43.7 CH2  43.8 CH2  36.8 CH2  43.7 CH2 
7 210.5 C  210.4 C  210.5 C  71.2 CH  210.0 C 
8 47.8 CH2  47.7 CH2  47.7 CH2  45.4 CH2  47.8 CH2 
9 27.4 CH  27.3 CH  27.3 CH  31.1 CH  27.4 CH 
9-Me 19.6 CH3  19.6 CH3  19.7 CH3  19.3 CH3  19.4 CH3 
10 146.3 C  146.3 C  146.3 C  146.8 C  146.1 C 
11 133.5 CH  133.5 CH  133.5 CH  133.8 CH  133.2 CH 
12 154.1 C  154.1 C  154.1 C  154.4 C  153.8 C 
13 130.1 C  130.0 C  129.8 C  ND
d
   ND
d
  
14 137.3 CH  137.3 CH  137.3 CH  137.0 CH  ND
d
  
15 156.1 C  156.0 C  156.1 C  156.2 C  155.8 C 
16 131.5 C  131.4 C  131.5 C  ND
d
   ND
d
  
17 137.7 CH  137.7 CH  137.7 CH  137.3 CH  ND
d
  
18 162.7 C  162.7 C  162.7 C  162.9 C  162.4 C 
19 116.9 CH  116.8 CH  116.8 CH  115.9 CH  116.9 CH 
20 139.9 CH  140.0 CH  140.1 CH  141.4 CH  139.7 CH 
21 33.8 CH2  33.9 CH2  34.0 CH2  35.0 CH2  33.4 CH2 
22 79.9 CH  79.9 CH  79.9 CH  78.3 CH  79.6 CH 
22-OMe 57.7 CH3  57.7 CH3  57.8 CH3  58.1 CH3  57.6 CH3 
23 40.3 CH  40.3 CH  40.4 CH  41.0 CH  40.1 CH 
23-Me 9.0 CH3  8.9 CH3  9.0 CH3  9.0 CH3  9.0 CH3 
24 72.8 CH  72.9 CH  72.9 CH  72.6 CH  72.6 CH 
25 31.9 CH2  31.8 CH2  32.1 CH2  33.6 CH2  31.6 CH2 
26 81.7 CH  81.6 CH  81.1 CH  81.6 CH  81.4 CH 
26-OMe 58.0 CH3  57.9 CH3  58.1 CH3  58.0 CH3  57.8 CH3 
27 34.4 CH  34.7 CH  35.5 CH  34.5 CH  34.4 CH 
27-Me 15.4 CH3  15.5 CH3  15.4 CH3  15.7 CH3  15.6 CH3 
28 25.0 CH2  27.0 CH2  28.4 CH2  25.2 CH2  26.6 CH2 
29 39.8 CH2  30.4 CH2  29.7 CH2  39.8 CH2  30.3 CH2 
30 211.6 C  73.03 CH  70.0 CH  211.6 C  72.7 CH 
31 48.6 CH  37.5 CH  39.7 CH  48.6 CH  37.2 CH 
31-Me 13.3 CH3  9.7 CH3  8.5 CH3  13.6 CH3  9.1 CH3 
32 77.2 CH  79.8 CH  79.3 CH  77.2 CH  76.4 CH 
32-OAc 170.0 C  170.6 C  172.5 C  170.0 C  171.1 C 
32’’ 20.8 CH3  20.9 CH3  20.9 CH3  20.9 CH3  20.8 CH3 
33 36.8 CH  36.9 CH  36.5 CH  36.9 CH  36.7 CH 
33-Me 18.8 CH3  19.3 CH3  19.4 CH3  19.0 CH3  19.4 CH3 
34 110.4 CH  110.2 CH  110.0 CH  110.5 CH  109.5 CH 
35 129.4 CH  129.4 CH  129.4 CH  129.4 CH  129.4 CH 
35-NMe 27.5 CH3  27.5 CH3  27.5 CH3  27.5 CH3  27.5 CH3 
35-NCHO 162.1 CH  162.1 CH  162.1 CH  162.1 CH  161.9 CH 
36    170.2 C        170.3 C 
37    80.6 CH        81.4 CH 
37-OMe    58.6 CH3        58.2 CH3 
38     72.98 CH2        62.9 CH2 
38-OMe    59.3 CH3          
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a
Carbon spectra recorded at 125 MHz.
 b
Resonances for minor rotamers can be found in the supporting information.
 
c
Carbon resonances extrapolated from HSQC and HMBC experiments.  
d
Not detected.  
 
All new compounds provided 
1
H NMR spectra consistent with tris-oxazole macrolides. These 
characteristic signals included the presence of a minor rotamer in an approximate 2:1 ratio 
evidenced by doubling of the signals for the N-methyl group (H 3.02 and 3.06; 35-NMe) and 
formamide proton (H 8.29 and 8.07; 35-NCHO). This doubling arises from the slow 
interconversion of the s-cis- and s-trans- rotamers of the tertiary amide and has been documented 
in molecules containing similar tail regions including tolytoxin,
45
 scytophycins,
46
 luminaolide,
47
 
and rhizapodin.
48
 Additionally, for compounds 2.3-2.5, the deshielded 
1
H NMR signals for H-11, 
H-14, and H-17 (Table 1) were consistent with the three contiguous 2,4-disubstituted oxazole 
rings.  Co-isolation of 2.1-2.2 from this egg mass supported the conclusion that 2.3-2.5 were 
ulapualide analogs. In addition, 2.1-2.5 contained the same UV chromophore with a maximum at 
249 nm and produced a consistent pattern of ESI-MS cations including [M+H-H2O]
+
, [M+H]
+
, 
[M+NH4]
+
, and [M+Na]
+
 where the [M+H]
+
 were the least abundant. 
High resolution mass spectrometry of 2.3 produced a protonated molecule at m/z 883.4700 
[M+H]
+
. This datum is consistent with a molecular formula of C46H66N4O13 for the parent 
molecule. Comparison to the 
1
H NMR spectrum of 2.1 indicated 2.3 contained two more protons, 
while the 
13
C NMR spectrum of 2.3 contained an additional sp
3
 oxygenated carbon C 70.0 (C-
30; 2.3) at the expense of a keto group at C 211.6 (C-30; 2.1). HMBC correlations from the 
methyl group at position 31 to C-30 confirm the keto group on the aliphatic tail of 2.1 was 
reduced rather than the one in the macrolide ring. 
High resolution mass spectrometry of 2.4 provided a protonated molecule at m/z 883.4662 
[M+H]
+
 as well. Comparison between the NMR data of 2.4 and 2.1 showed an additional 
oxygenated sp
3
 carbon C 71.2 (C-7; 2.4) and a corresponding proton signal at H 4.07 (H-7; 2.4) 
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again at the expense of a carbonyl resonance C 210.5 (C-7; 2.1). COSY correlations from the 
methyl group at position 9 to H-9 and from H2-8 to both H-9 and H-7 support the conclusion that 
C-7 was a secondary alcohol in 2.4. 
High resolution mass spectrometry of 2.5 gave a protonated molecule at m/z 985.4976 [M+H]
+
 
consistent with the molecular formula (C50H72N4O16) 14 amu smaller than 2.2. Comparison of 
the 
13
C and 
1
H NMR spectra of 2.5 with 2.2 indicated that 2.5 contained one less methoxy group. 
Taken together, the data suggested 2.5 contained a hydroxy rather than methoxy group. HMBC 
correlations from the existing OMe groups in 2.5 pinpoint the placement of the methoxy groups 
and through deduction that C-38 was a primary alcohol. 
2.1.2. Relative and Absolute Configurations of Ulapualides A-E 
 
The relative and absolute configurations of 2.3-2.5 could not be determined due to the limited 
amount of material available. In mass limited cases, configurational assignment based on carbon 
chemical shift comparisons with known analogs is a common tactic. In this case, synthetic 
studies have demonstrated that this approach is unreliable for distinguishing diasteromers within 
to this family of natural products.
49
 However, all of the tris-oxazole compounds characterized by  
X-ray crystallography have the same absolute configuration (with the omission of position 9).
50 
This suggests that those stereocenters are conserved via a shared biogenesis. In addition, the two 
other stereocenters in 2.5 are most likely 30R,37R consistent with 2.2 and the structurally-related 
mycalolides.
51
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2.2. Bioactivity of Ulapualides A-C 
Compounds 2.1-2.3 were tested against select cancer cell lines within the NCI 60-cell panel. 
These included human renal cell adenocarcinoma (768-0), prostate carcinoma (DU-145), 
mammary gland adenocarcinoma (MDA-MB-231) and lung carcinoma (A549) cell lines. 
Samples were tested in triplicate in two independent trials. For the second independent 
experiment, the concentration was determined through colorimetry using a standard curve made 
from the more abundant 2.2. As expected, low to sub-micromolar IC50 values were observed for 
all samples (Table 3). The activities of 2.1-2.2 were similar in all cell-lines tested, while 2.3 was 
two to four times less potent. Removal of methyl or methoxy groups from the tail region or the 
introduction of charged groups is predicted to decrease binding affinity to G-actin which is 
dominated by hydrophobic interactions in the cleft between actin subdomains 1 and 3.
42
 The 
observed decrease in activity could be attributed to replacement of the modified glycerate or keto 
group with a more polar hydroxy group. 
Table 2.3. IC50 Values of Ulapualides A-C (2.1-2.3) Against Select NCI Cell Lines (μM) 
 768-0  DU-145  MDA-MB-231  A549 
 Trial 1 Trial 2  Trial 1 Trial 2  Trial 1 Trial 2  Trial 1 Trial 2 
Ulapualide A (2.1) 0.28 0.26  0.26 0.25  0.25 0.23  0.28 0.29 
Ulapualide B (2.2) 0.26 0.66  0.28 0.34  0.29 0.29  0.33 0.26 
  Ulapualide C (2.3) 1.1 1.4  0.76 0.85  0.58 0.76  0.68 0.60 
 
 
2.3. Comments on Ulapualides 
With the exception of the kabiramides, also isolated from nudibranch eggs, all other tris-
oxazole containing molecules were isolated from sponges suggesting that these molecules may 
be sequestered through predation. The support for this hypothesis includes observed predation of 
17 
 
Halichondria sp. by Hexabranchus sanguineus, isolation of dihydrohalichondramide from both 
species, and sequestration of dihydrohalichondramide in the mantle and the digestive 
system/gonad of the nudibranch.
52
 That similar tris-oxazole compounds have been isolated from 
sponges of dissimilar phylogeny suggests the ultimate source may be microbial as was found 
with the bryostatins, metabolites originally isolated from the bryozoan Bugula neritina
53
 and 
later discovered to be a product of the symbiont Endobugula sertula.
54
 The symbiont E. sertula 
is vertically transmitted from bryozoan adult to embryo
55
 and provides chemical defenses for the 
otherwise unprotected larvae.  
Compound 2.3 could be an artifact as hydrolysis of the O-methylated glycerate in 2.2 would 
yield the free alcohol 2.3. That significant amounts of 2.3 can be observed via LCMS in the 
original MeOH:CH2Cl2 extract, before buffers were used suggests this is not the case. 
Furthermore, treatment of 2.2 in a 2:1 mixture of MeOH:H2O with 0.1% formic acid for seven 
days yielded no hydrolysis product detectable by LCMS. 
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CHAPTER 3 
3. Bioactivity Guided Isolation of Metabolites Isolated From Callyspongia 
3.1. Overview of Polyacetylenes 
As part of our search for beta secretase (BACE1) inhibitors, the crude fractionation of a sponge 
extract collected from Maui displayed potent activity (98% inhibition at 30 μg/mL). Interestingly, 
no activity was observed by morphologically similar sponges collected from other locations on 
Maui. Only those samples collected at Black Rock, Maui consistently inhibited BACE1. A bio-
assay guided fractionation led to the isolation of a pair of long chain polyacetylenes, known 
compound 3.1 (callyspongynic acid) and new compound 3.2 (decarboxycallyspongynic acid). 
 
Figure 3.1 Polyacetylenes Isolated from Callyspongia sp. 
Long chain polyacetylenes are polyketides of varying chain length, from C16-C46, that differ 
from each other by varying numbers of hydroxy groups and cyclizations. Many of these long 
chain polyacetylenes are axisymmetric or exhibit central symmetry, and these compounds are 
considered characteristic chemical markers of Petrosia sponges.
56
 Others are asymmetric and 
although there have been a few cases of this type of metabolite isolated from different plants
57
 
and animals,
58
 the order Haplosclerida are the main source of these molecules. As such, 
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asymmetric long chain polyacetylenes are considered a chemotaxonomic markers for some 
genera within this order including Petrosia, Xestospongia, and Callyspongia.
56
 
A recent review compiled more than 600 polyacetylenes isolated from marine algae and 
invertebrates throughout the past five decades.
56
 This simple structural class of compounds 
displays a variety of biological activities including antifungal,
59
 antimicrobial,
60
 HIV reverse 
transcriptase inhibition,
61
 and cytotoxicity.
62
 Additionally, polyacetylenes have many ecological 
roles, including inhibiting starfish gametes,
63
 preventing fouling by barnacle larvae and inducing 
metamorphosis of ascidian larvae.
64
   
A subtype of marine polyacetylenes contains a 1-yne-3-ol moiety,
 65
 very similar to 
callyspongynic acid (3.1) and decarboxycallyspongynic acid (3.2). The terminal propargylic 
alcohol is responsible for the strong cytotoxicity observed from extracts containing these 
molecules.
66
 SAR studies established that the flanking unsaturation and the absolute 
configuration of the carbinol play a significant role, as the  (3R,4E)-en-1-yn-3-ol pharmacophore 
displayed the more potent submicromolar activity against HTC116 cells.
67 , 68
 Various 
antiproliferative mechanisms were demonstrated by one member of this class, dideoxypetrosynol 
A,
69
 including inhibition of DNA replication,
70
 inhibition of cyclooxygenase-2 and telomerase 
activity,
71
 and  induction of cyclin-dependent kinase inhibitor p16 and down regulation of 
retinoblastoma protein phosphorylation.
72
  
 
Figure 3.2 Dideoxypetrosynol A.  Dideoxypetrosynol A exhibits two (3R,4E)-en-1-yn-3-ol moieties and displays 
submicromolar activities against HT116 cells. 
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3.1.1. Isolation and Structure Elucidation of 3.1 and 3.2 
8.0 g of sponges were extracted with 1:1 MeOH:CH2Cl2 overnight three times. The resultant 
extract was subject to a modified Kupchan partitioning and the active CH2Cl2 layer was dry 
loaded on C8 silica gel before elution with a step gradient of increasing MeOH in H2O. The most 
potent fraction, 75% MeOH, was then subjected to reversed-phase HPLC. The subsequent 14 
fractions were again tested against BACE1. The most active fraction was comprised of one 
major compound (3.1), as determined by 
1
H NMR, that had a weak UV chromophore and 
ionized poorly during positive mode ESI analysis. APCI-LCMS yielded a sodium adduct at m/z 
493.2729 and a dehydrated protonated molecule with m/z 453.2820. Both ions are consistent 
with the molecular formula C32H38O3 and 14 degrees of unsaturation. The large number of 
signals in the 
13C NMR between δC 62 and 84 (13) coupled with only a single oxygenated proton 
signal in the 
1
H NMR, suggested 3.1 was a polyacetylene. Dereplication through Anti-Marin
73
 
using the LCMS, 
1
H and 
13
C NMR data established it was the known compound callyspongynic 
acid (3.1).
74
 
In addition to 3.1, 3.2 was isolated and characterized. High resolution mass spectrometry of 3.2 
yielded a faint ion with m/z 427.3010 and a more abundant ion 409.2912 consistent with the 
protonated ions [M+H]
+
 and [M+H-H2O].
+
  These data indicated a molecule with molecular 
formula of C31H38O and 13 degrees of unsaturation. The NMR spectra of 3.2 contained many of 
the same chemical proton and carbon resonances as 3.1, most notably those belonging to the 
propargylic alcohol (positions 27-32). With one fewer degree of unsaturation and being by 46 
amu smaller than 3.1,, 3.2 was hypothesized to be a decarboxy version. This is supported by the 
absence of a carboxyl carbon resonance at δC 163.1 (C-1; 3.1, not shown). Also, 3.2 was 
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determined to have a second terminal alkyne based on the observed 
1
JCH and 
2
JCH from H-2 of 
247.8 Hz and 48.9 Hz to C-2 and C-3, respectively. 
 
Table 3.1. NMR Spectroscopic Data for 3.2 (CD3OD) 
   3.2   
Position C
a
 Type H
b
 (J in Hz) COSY HMBC (
1
H to 
13
C)
 
2 69.5 CH 2.17, m   
3 85.0 qC    
4 19.0 CH2 2.17, m   
5 29.1
c 
CH2 1.51, m   
6 29.4
c 
CH2 1.51, m   
7 29.3
c 
CH2 1.51, m   
8 19.3 CH2 2.14, m   
9 81.3 qC    
10 80.2 qC    
11 18.48 CH2 2.24, m   
12 29.8 CH2 1.60, p (6.9) H-11/H-13
d 
C-10, C-11,
d
 C-13,
d
 C-14   
13 18.51 CH2 2.24, m   
14 81.1 qC    
15 80.1 qC    
16 18.6 CH2 2.24, m   
17 29.0 CH2 1.65, p (6.9) H-16,
d
 H-18
 
C-15, C-16,
d
 C-18 C-19  
18 18.8 CH2 2.35, t (6.9) H-17  
19 77.0 qC    
20 66.7 qC    
21 66.3 qC    
22 78.0 qC    
23 19.7 CH2 2.25, m   
24 29.4 CH2 1.51, m   
25 29.6 CH2 1.42, p (3.3)   
26 29.7 CH2 1.42, p (3.3)   
27 32.8 CH2 2.08, br q (6.4) H-26,
d
 H-28 C-25, C-28, C-29 
28 133.9 CH 5.85, dtd (15.1, 6.8, 1.3) H-27, H-29 C-26, C-27, C-30 
29 130.8 CH 5.56, ddt (15.1, 6.1, 1.3) H-28, H-30 C-27, C-30, C-31 
30 63.1 CH 4.74, br d (6.1) H-29 C-28, C-29, C-31, C-32 
31 84.7 qC    
32 74.6 CH 2.86, d (2.3) H-30 C-29, C-30 
a
Carbon spectra recorded at 125 MHz.
 b
Carbon spectra recorded at 125 MHz. 
c
Positions cannot be conclusively 
determined. 
d
Correlation is to a value that is overlapped.  
 
3.1.2.  Relative and Absolute Stereochemistry of 3.1-3.2 
For new compound 3.2, absolute chemistry of the lone stereocenter at position 30 was not 
conclusively determined due to insufficient material to perform a Mosher’s analysis. Attempts to 
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assign the configuration based upon comparisons of optical rotations with known and proven 
structures were conducted.   
Corticatic acid A (3.3) is a polyacetylene with only one stereocenter and structural features 
similar to 3.1. Reported specific rotations of 3.3 are +28 in CHCl3
75
 and -18 in MeOH. The 
decarboxy version of 3.3, corticatynol A (3.4), displayed a specific rotation of -12 in CHCl3.
76
 In 
all reports, the compounds were confirmed by Mosher’s analysis to be the R enantiomer. The 
observation that the specific rotation of 3.3 changed sign in aprotic vs. protic solvents while 3.4 
displayed a specific rotation of opposite sign in an aprotic solvent sparked the hypothesis that the 
sign of the specific rotation was an effect of hydrogen bonding. The hypothesis was that 
hydrogen bonding between the carboxylic acid and the lone alcohol may induce a secondary 
structure which creates a specific rotation opposite in sign to that when the hydrogen bonding is 
disrupted through interactions with the solvent, whereas the decaboxy congeners would not 
change sign. These interactions would presumably be intramolecular or through small aggregates.  
 
Figure 3.3 Optical Rotation Analysis of 3.1 and 3.2. A) Potential intramolecular or small aggregate hydrogen bonding in 3.1. 
B) Observed and measured [α] of poly acetylenes and their decarboxy congeners in protic vs. aprotic solvents. 
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  Initially, the data seemed to support this hypothesis. The specific rotation of 3.2 (-9.5, EtOH) 
was similar magnitude but opposite in sign to the reported optical rotation of 3.1 (+5.4, EtOH) in 
the protic solvent, suggesting that the lone stereocenter is epimeric to 3.1. As a follow up, the 
observed optical rotations of both 3.1 and 3.2 displayed a negative sign in the aprotic solvent 
MeCN, supporting the observation that the sign will invert only for the carboxy analogue. 
However, in our collected sample, the optical rotation of 3.1 in EtOH displayed a negative sign (-
4.0, EtOH).  Thus, our hypothesis was disproved as 3.1 displayed the same sign optical activity 
in both protic and aprotic solvents. Instead, the negative sign suggested that the R enantiomer of 
3.1 was isolated and highlights the importance of obtaining optical rotations of all pure 
compounds isolated. 
To conclusively tell whether 3.1 isolated was the R or S enantiomer, the absolute configuration 
of 3.1 was to be determined. 
1
H NMR data of both the R and S Mosher’s esters of the saturated 
S-callyspongynic acid have been previously reported. Creating just the R Mosher’s ester of the 
hydrogenated product of 3.1 would yield either the R-S compound (identical to reported) or the 
R-R compound (enantiomeric to the reported S-S stereoisomer).  3.1 was hydrogenated using Pd 
on carbon under an atmosphere of H2, and the resultant saturated fatty acid was reacted with the 
R-Mosher’s acid chloride to create the S-Mosher’s ester.  Unfortunately, the absolute 
configuration continues to be ambiguous as the reaction failed to produce the intended product. 
 
3.2. Bioactivity of 3.1-3.2 
Callyspongynic acid (3.1) previously was reported to be a potent selective inhibitor of -
glucosidase (IC50 0.25 μg/mL) that was inactive against -glucosidase and -galactosidase.
74
 An 
important distinction since the in-house BACE1 assay would result in a false positive if the 
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compound inhibited -galactosidase. Callyspongynic acid (3.1) displayed 95.3% inhibition of 
BACE1 at 64 μM while the other compounds were inactive against BACE1 at 30 μg/mL. 
Unfortunately, no IC50 values were determined due to the discontinuation of our assay kit. 
Attempts at using an assay with an orthogonal mechanism (FRET vs. EFC) for BACE1 failed to 
provide meaningful results.  Using two different batches of the kit, we were unable to 
demonstrate inhibition of BACE1 using either of two positive controls, both of which were 
commercial BACE1 inhibitors and one of which we had been using for years. 
 Additionally, 3.1 and 3.2 inhibited pancreatic cell growth with an IC50 of 15 and 1 µM, 
respectively. Both IC50 curves display Hill slopes of -10 indicating they are likely promiscuous 
aggregators.
118
 However, these steep Hill slopes are due to a lack of data points in the IC50 range 
and are needed for more accurate assessments. The biological activity data obtained suggests that 
both ends of 3.1 contain a pharmacophore. The carboxylic acid in 3.1 was previously proven to 
be necessary for activity with -glucosidase and is the case for BACE1. At the terminal end, the 
aforementioned 4-en-1-yn-3-ol moiety likely produces the observed cytotoxicity. 
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Figure 3.4 IC50 Curves for 3.1 and 3.2 With Panc-1 Cells. 
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3.3. Comments on 3.1-3.2 
There are two biosynthetic proposals for the formation of acetylenic bonds. The first is through 
desaturation of an existing alkene through iron-catalyzed dehydrogenation with molecular 
oxygen. The second is the elimination of an activated enol carboxylate. Although most evidence 
to date comes from plants and supports the former, the latter was supported when Fleming 
demonstrated 3-hydroxy-2-alkene carboxylates eliminate to acetylenes under mild conditions.
77
 
A biosynthetic route for marine polyacetylenes has been proposed involving an offshoot of 
mycolic acid biosynthesis and extension of the Fleming hypothesis.
78
 The enol tautomer of the 
ketoacid could be converted into a good leaving group through phosphorylation. 
Decarboxylation can then eliminate the leaving group to create an acetylenic bond (Figure 3.5).  
 
Figure 3.5 Viable Polyketide Biosynthesis for Marine Polyacetylenes. This figure is adapted from Minto, R. E.; Blacklock, B. 
J. Prog. Lipid Res. 2008, 47, 233-306. 
Callyspongynic acid (3.1) was isolated from both of the sponge samples which displayed 
potent BACE1 inhibition. The limited amount of other two morphologically similar sponges 
have been exhaustively extracted and fractionated, and the resulting fractions sent for screening. 
At this time, we only have biomass left for one of those samples, which was subjected to LCMS 
analysis. This resulting ion chromatogram lacked a significant peak with a m/z of [M-H]
-
 469 
corresponding to 3.1. This suggests 3.1 is the likely causative agent for BACE1 inhibition. 
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However, as this datum is dependent on the accurate storage of our extract and since the 
entireties of these sponges have already been used, taxonomical and/or metabolomic analyses are 
still necessary to confirm this hypothesis and is pending on collection and isolation of more 
sponge.  
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CHAPTER 4 
4. New Diterpene Isolated From a Hawaiian Sponge of Genus 
Myrmekioderma  
4.1. Overview of Metabolites Isolated from Myrmekioderma 
Although a large diversity of terpenoid and steroidal compounds have been isolated from 
marine invertebrates, few derivatives of the pregnane class of compounds have been 
reported.
79,80,81,82
  The most recent report being a set of pregnane-10,2-carbolactones isolated by 
our group.
83
 Oxidation of the A ring into phenol pregnane derivatives are even rarer, and lead to 
bioactivities ranging from barnacle larvae lethality
84
 to antimalarial.
85
 Initial screening of an 
undescribed Hawaiian sponge belonging to the genus Myrmekioderma and collected off the 
southern coast of Lanaʻi displayed moderate activity against HSV-1 and strong activity against 
VSV at 200 μg/mL. When extracted on a larger scale, all fractions failed to reproduce this 
activity. Therefore, a chemical investigation of the sponge was conducted, the fruits of which 
yielded myrmenaphthol A, 4.1, and known compounds 4.2-4.4. Cinanthrenol A (4.2) was 
previously isolated from the sponge Cinachyrella sp.
86
 while 3,4-dihydroxypregna-5,17-diene-
10,2-carbolactone (4.3) and 3,4-dihydroxypregna-5,20-diene-10,2-carbolactone (4.4) were 
previously isolated from Strongylophora sp. (Haplosclerida).
83
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Figure 4.1 Pregnane Derivatives Isolated from the Marine Sponge Myrmekioderma sp.  
 
4.1.1. Isolation and Structure Elucidation New Compound 
Myrmenaphthol A, 4.1 
Myrmenaphthol A, 4.1, was isolated as an amorphous yellow powder after multiple rounds of 
chromatography of the 75% MeOH fraction. High resolution mass spectrometry provided a 
protonated molecule with m/z 307.1135 [M+H]
+
. This datum is consistent for a compound with 
the molecular formula C20H18O3, indicating 12 degrees of unsaturation. The 
13
C NMR spectrum 
displayed 14 sp
2
 non-carbonyl carbons and the HMBC spectrum displayed an additional sp
2
 with 
a chemical shift indicative of an -unsaturated ketone (C-16 190.9). Therefore, the molecule 
has seven double bonds, a ketone, and four rings to account for the degrees of unsaturation. 
The structure of 4.1 was assembled by COSY and HMBC correlations. H-6 showed a COSY 
correlation to H-7 as well as HMBC correlations to C-4,-5,-7,-8, and -10 to help establish part of 
fragment 1. This fragment was completed with a COSY correlation from H-4 to H-3. A COSY 
correlation between H-11 and H-12, HMBC correlations from H-19 to C-13,-18,-17, and -16 and 
HMBC correlations from H-20 to C-12,-14, and -17 allowed the assembly of fragment 2.   
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Figure 4.2 Key HMBC and COSY Correlations of 4.1.  Key HMBC and COSY correlations leading to the construction of 
fragments 1-3 and the overall structure elucidation of 4.1. 
 More HMBC correlations from H-1 to C-2,-3,-5 and -9 created the phenol A ring while 
correlations from H-11 to C-8,-9, and -10 connected fragments 1 and 2 to create the naphthyl 
nucleus. Correlations from H-7 to C-14 then extended the ring system to create fragment 3. At 
this point, the only remaining pieces in our chemical inventory were a quaternary carbon (C 
149.6, C-15), an oxygen, a hydrogen and one degree of unsaturation. Therefore, the only existing 
option was to create an -hydroxyketone moiety by inserting the enol between carbons 14 and 
16 while closing the ring to create structure 4.1. 
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Table 4.2: NMR Spectroscopic Data for 4.1 (CD3OD) 
    4.1   
Position C
a
 Type H
b
 (J in Hz) COSY HMBC (
1
H to 
13
C)
 
ROESY 
1 106.8 CH 7.33 d (2.2) H-3  2, 3, 5, 9 H2-11 
2 157.1  C     
3 119.5 CH 7.09 dd (8.8, 2.2) H-1, H-4 2, 5  H-4 
4 131.1 CH 7.70 d (8.8) H-3 1, 2, 5, 6, 9, 10  H-3 
5 129.6 C     
6 127.2 CH 7.64 d (8.6) H-7 4, 5, 7 , 8, 10 H-7 
7 124.6 CH 8.07 d (8.6) H-6 5, 8, 9, 10, 14 H-6 
8 128.3 C     
9 131.8 C     
10 134.7 C     
11a 
11b 
 24.8  CH2 3.32 m 
3.22 m 
H-12 b 
H2-12 
8, 9, 10, 12, 13 
8, 9, 10, 12,  
H-1, H-11 
H-1, H-11, H-20 
12a 
12b 
 33.0 CH2 2.68 dd (13.0, 6.1) 
1.82 td (12.5, 6.4) 
H-11b, H-12b 
H2-11, H-12a 
9, 11, 13, 14 
11, 13, 20 
H-11b, H-12, H-19, H-20 
H-12a 
13  40.7 C     
14 143.1 C     
15 149.6 C     
16 190.9
c
 C     
17 144.1  C     
18 130.7 CH 6.63 q (7.5) H-19 13, 16, 17, 19 H-19 
19  14.8 CH3 2.05 d (7.5) H-18 13, 16, 17, 18 H-12a, H-18, H-20 
20  22.3 CH3 1.31 s  12, 13, 14  H-11b, H-12a, H-19 
a
Carbon acquired at 125 MHz. 
b
Proton acquired at 500 MHz. 
c
Carbon acquired by HMBC experiment 
 
The relative configuration was determined through analysis of ROESY correlations. A ROESY 
correlation between H-20 and H-19 determined the geometry of the pregnene’s C-17 double 
bond to be E. Further ROESY correlations from H-20 to H-11b suggested a cis orientation and 
correlations from H-20 to H-12a but not H-12b suggested that the methyl group adopts a 
conformation in which it is pseudo-axial. This is supported by the MM2 minimized energy 
conformer shown in Figure 4.3B. 
A)  B)  
Figure 4.3 Absolute Configuration of 4.1. A) NOE correlations from H-20 to H-19 is evidence the geometry of C-17 olefin is E. 
B) MM2 minimized energy conformer of the S conformer of 4.1 as seen looking down the carbonyl bond. 
31 
 
 The absolute configuration of 4.1 was determined through CD spectroscopy. Applying the 
octant rules
87
 as described by Djerassi, Moffitt, Klyne, Moscowitz and Woodward to the MM2 
minimized energy conformer of 4.1 suggests that 4.1 should yield a negative cotton effect for the 
S conformer and a positive cotton effect for the R conformer. Figure 4.3B shows the minimized 
energy conformer of the S enantiomer looking down the carbonyl bond. While the methyl (C-20) 
lies in the top right negative quadrant and the two opposing methylenes (C-11,-12) in the bottom- 
right positive quadrant, the bulk of the naphthyl substituent exists in the bottom-left negative 
quadrant. Additionally, time-dependent density functional theory (TDDFT)
88,89
 calculations were 
performed using Gaussian09 to predict CD spectra for the S enantiomer. TDDFT calculations are 
becoming a more commonly used technique for determining absolute configuration of various 
natural products of different classes.
90
 Conformational analysis of 4.1, a rigid molecule, 
displayed four conformers which differed only in the direction of the two oxygen-hydrogen 
bonds. The two conformers with the -hydroxy proton in position to hydrogen bond to the 
carbonyl accounted for 99.7% of the conformers.  The predicted CD spectra of these two major 
conformers supported a negative cotton effect at 360 nm.  Experimentally, a negative cotton 
effect was indeed observed confirming an S configuration for the molecule’s lone stereocenter at 
position 13.  
 
Figure 4.4 Predicted and Observed CD Spectra of 4.1.  
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4.1.2.  Isolation of Known Compounds 4.2-4.4  
In pursuit of obtaining more 4.1 from adjacent fractions, HPLC of the 50% MeOH fraction 
displayed multiple easy to isolate peaks when monitoring 280 nm. Collection of these peaks 
yielded 4.2 as a pure compound and both 4.3 and 4.4 as mixtures. 
The first, 4.2, shared many of the same proton resonances as 4.1. Perhaps the biggest similarity 
was 4.2 displayed resonances consistent with the 2-napthol spin system. HRMS provided a 
protonated molecule with m/z of 291.1386 in agreement with the molecular formula of C20H18O2 
and 12 degrees of unsaturation. This coupled with two additional aromatic doublets facilitated 
our dereplication efforts to establish 4.2 as the known compound cinanthrenol A.  
 As they did not contain any aromatic signals, both 4.3 and 4.4 belonged to a different 
structural family. Having recently isolated multiple pregnanes from a similar sponge, the 
1
H 
NMR spectrum of 4.3 and 4.4 were quickly determined to be consistent with 10-2-carbolactone 
pregnanes. Key characteristics in the 
1
H NMR spectrum include three resolved, sharp doublets 
(δH 3.82, 4.36, and 4.65 ppm) correlating to the three contiguous oxygenated centers (positions 
2-4) and a sharp doublet at δH 1.62 ppm corresponding to position 2. Both compounds produced 
a sodiated adduct [M+Na]
+
 with m/z of 367.1885, consistent with the molecular formula 
C21H28O4.  Among other evidence, the 
1
H NMR of 4.4 displayed only a single methyl signal (δH 
0.81 ppm, s), i.e. it contained a terminal exocyclic vinyl group not the methyl-substituted 
exocyclic vinyl group. As such, it was determined to be to be 3,4-dihydroxypregna-5,20-diene-
10,2-carbolactone. In contrast, the 
1
H NMR of 4.3 displayed two methyl signals (δH 0.98 ppm, s; 
δH 1.31, d) consistent with 3,4-dihydroxypregna-5,17-diene-10,2-carbolactone containing the 
methyl-substituted exocyclic double bond. 
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4.2. Biological Activity of 4.1-4.2  
Previous studies have shown 4.2 to have affinity for estrogen receptors. Cinanthrenol A
86
 was 
formerly isolated from a sponge dredged from the depths of the East China Sea, Japan. The 
phen-anthracene compound previously displayed strong cytotoxicity against P-388 and He-La 
cells with IC50 values of 4.5 and 0.4 μg/mL respectively. Its strongest affinity was to estrogen 
receptor (ER1) which displayed competitive binding against estradiol with an IC50 of 10 nM.
86
 
Ent-(+)-cinanthrenol A has recently been published, confirming natural cinanthrenol A’s 
absolute stereochemistry and providing a pathway to synthesizing structural analogues.
91
 Due to 
4.1’s similar framework to 4.2, testing of 4.1 and 4.2 against ER1 was conducted in parallel. 
Unexpectedly, no significant inhibition was displayed for either compound, with only 30% 
inhibition at 100 μM.  
 
4.3. Comments on Compounds 4.1-4.4 
Compound 4.1 displays an uncommon naphthyl nucleus in a traditional steroid ring system, 
which to the author’s knowledge, represents the first example from a marine source. One of the 
few terrestrial examples of this moiety appears in equilenin,
92
 a potent estrogen receptor activator 
and minor component of the FDA approved drug Premarin. A major difference of 4.1 from 
nearly all similar natural products is the oxidation of the A ring. Equilenin, like many known 
biological hormones such as testosterone and estradiol, have oxidation on the 3 position whereas 
4.1 has oxidation of the 2 position.  This rare oxidation of a steroid nucleus is only known to 
occur in cinanthrenol A, which has been isolated simultaneously with 4.1.  
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Figure 4.5 Structures of Equilenin, 4.1 and 4.2 for Comparison. 
A hypothetical biosynthetic route is proposed for the conversion of 4.1 to 4.2. The sp
3
 methyl 
group (C-18) is oxidized off (4.5-4.6) and then a methylene unit added back on to create the 
cyclopropyl group through a SAM mechanism similar to fatty acid biosynthesis (4.6-4.8).
93
 A 
base catalyzed dehydration of 4.8 yields 4.9 and a simple asymmetric reduction of 4.9 yields 
cinanthrenol A (4.2). 
 
Figure 4.6 Plausible Biosynthetic Scheme of 4.1 to 4.2.   New compound 4.1 is a potential precursor to Cinanthrenol A (4.2) 
which may arise after oxidation, SAM methylation, and a series of base catalyzed reactions. 
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CHAPTER 5 
5. Bioactivity Guided Isolation of Metabolites Isolated From an Unidentified 
Hawaiian Sponge 
5.1. Overview of Drimane and Friedodrimane Diterpenes 
Friedodrimanes and other likely modified sesquiterpenoid ring units connected to a quinone or 
hydroquinone are a common moiety isolated from marine sponges and algae. Among the most 
well-known of these classes are avarol
94
 and ilimaquinone.
95
 A variety of biological activities 
have been reported for these compounds, including antileukemia activities, cytotoxicity (killing 
either coral polyps and/or fish), and possible anti-human immunodeficiency virus agent (HIV).
96
 
The bioactivity of terpenylquinones is likely due to the quinones’ redox potential and/or ability 
to partake in Michael-type addition-elimination reactions.
97
 The cytotoxicity may result from 
redox cycling and the production of reactive oxygen species (ROS) which could go on to damage 
tumor cells.
98,99
 Support for the mechanism of antitumor action by ROS was previously obtained 
with avarone (5.4) and avarol (5.1),
100,101
 although there was also evidence of the relevance of 
arylation of proteins.
97,102,103
 Comprehensive reviews on these classes of compounds and their 
biological activity have been published by Gordaliza,
104
 Sladić and Gašić,105 and Marcos et al.106 
Crude fractions of an extracted, unidentified Hawaiian sponge displayed moderate inhibition of 
BACE1. The fraction contained one major peak, a mixture of 5.1 and 5.2. Further chemical 
investigation of the sponge yielded 5.3 and 5.4 as mixtures, along with two new pure  
compounds, 5.5-5.6.  
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Figure 5.1 Compounds Isolated From Unidentified Hawaiian Sponge. 
 
5.1.1. Isolation and Structure Elucidation of 5.5 and 5.6 
Bioactivity guided isolation led to a 3:2 mixture of compounds which displayed moderate 
BACE1 inhibition. HRMS of this mixture only showed predominantly a single protonated 
molecule [M+H]
+
 with m/z of 315.2325 consistent with the molecular formula C21H30O2.  Initial 
attempts to purify this mixture, including size exclusion, crystallization, and normal phase 
HPLC, ultimately failed. However, these attempts cleaned the mixture to a 4:1 ratio which 
allowed for the dereplication of the major compound, avarol (5.1). Only after a lengthy round of 
reversed-phase HPLC using a pentafluorophenyl column and multiple injections of microgram 
amounts allowed for the isolation of small quantities of pure 5.2. With a pure sample in hand, 
dereplication quickly showed that 5.2 was the known compound isoavarol.  
Preparative HPLC of the parent fraction was conducted to remove the major compounds in 
order to investigate the smaller components of the extract, yielding two more mixtures of 
compounds. The first, 5.3, contained the same aromatic 
1
H NMR corresponding to the 1,2,5 
substituted benzene but displayed an additional methyl singlet. Furthermore, LCMS produced a 
deprotonated ion [M-H]
-
 at m/z 355.2272 consistent with the molecular formula C23H32O3, or 
C2H2O larger than 5.1. It was then apparent 5.3 was avarol monoacetate. The second, 5.4, 
displayed a protonated molecule with m/z of 313.2158, consistent with the molecular formula 
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C21H28O2 and one degree of unsaturation more than 5.1. Dereplication of 
1
H NMR signals 
determined 5.4 was avarone. Minor compounds existed in both fractions of 5.3 and 5.4 as can be 
seen in the doubling of the two doublets (δH 2.59 and 2.73, H2-11) in a similar way of 5.1 and 
5.2.  These minor compounds are presumably their isomeric congeners with an exocyclic olefin. 
Further evidence for this assertion includes the appearance of minor carbon resonances at δC 
159.9 and 105.7 in the 
13
C NMR of 5.3 and proton resonances at δH 4.42 and δH 4.72.  As known 
compounds, these were left impure due to the lengthy HPLC needed to separate these isomers.  
Chemical exploration into a different fraction yielded a mixture of two more compounds, 5.5 
and 5.6. Similar aromatic and methyl signals suggested 5.5 to be an analogue of 5.1. HRESIMS 
of 5.5 displayed a protonated molecule [M+H]
+
 with m/z of 329.2095, consistent with the 
molecular formula C21H29O3 and contained only an extra oxygen in comparison to known 
compound 5.1. Comparison of the 
1
H NMR spectrum of 5.5 to 5.1 indicated 5.5 contained an 
oxygenated methine (δH 4.27, H-3). COSY correlations from H-3 to H2-2 coupled with HMBC 
correlations from H-3 to C-2, C-4, and C-15 suggested the oxygenation was at the 3 position.  
 
Figure 5.2 Key COSY and HMBC Correlations of 5.5 
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Table 5.1: NMR Spectroscopic Data (500 MHz, CD3OD) for 3-hydroxyisoavarol (5.5) 
    3-hydroxyisoavarol (5)    
position C
a type H, (J in Hz)
b COSY
b 
HMBC
b
 (
1
H to 
13
C) 
1a 22.9 CH2 2.28, dq (13.5, 2.5) H-10, H-2b, H-1b C-5 
1b   1.59, qd (13.3, 3.3) H-10, H2-2, H-1a C-3, C-5, C-10 
2a 38.16 CH2 2.11, m H-3, H-2b, H-1b C-3, C-4 
2b   1.28, m   
3 70.5 CH 4.27, ddt (12.0, 5.5, 1.7) H2-2, H2-15 C-2, C-4, C-15 
4 163.3 qC    
5 41.5 qC    
6 38.24 CH2 1.47, m   
7a 28.7 CH2 1.49, m   
7b   1.42, m   
8 37.3 CH 1.51, m   
9 43.0 qC    
10 49.2 CH 0.99, dd (12.1, 2.3) H2-1 C-9, C-12, C-15 
11a 38.3 CH2 2.67, d (13.9) H-11b C-8, C-9, C-10, C-12, C-16, C-17, C-21 
11b   2.46, d (13.9) H-11a C-8, C-9, C-10, C-12, C-16, C-17, C-21 
12 18.1 CH3 0.84, s  C-8, C-9, C-10, C-11 
13 18.0 CH3 1.02, d (6.0)  C-7, C-8, C-9 
14 21.5  CH3 1.05. s  C-4, C-5, C-6, C-10,  
15 100.1 CH2 4.83, t (1.55) H-15b, H-3 C-3, C-4, C-5  
   4.55, brs  C-3, C-5 
16 127.2 qC    
17 150.7 qC    
18 116.4 CH 6.53, d (8.6)  C-16, C-20 
19 114.5 CH 6.43, dd (8.6, 3.0)  C-17, C-21 
20 150.1 qC    
21 120.1  CH 6.48, d (3.0)  C-11, C-17, C-19 
 
a
Carbon spectra recorded at 125 MHz. 
b
Proton spectra recorded at 500 MHz.   
 
HRESIMS of 5.6 displayed a protonated molecule with m/z 327.1946 [M+H]
+
 consistent with 
the molecular formula C21H27O3, two protons short of 5.5. HMBC correlations indicated 5.6 
contained a keto group (δC 202.4, C-2), the only additional sp
2
 carbon, and no resonances 
indicative of an sp
3
 oxygenated carbon. This suggested the primary difference was the 
replacement of an alcohol with a keto group. HMBC correlations from H3-15 to C-3,-4,-5 and 
H3-14 to C-4,-5,-6,-10 helped determine the keto group to be on position 2 and -unsaturated. 
At first glance, a carbon chemical shift of 176.7 ppm (C-4) is quite unusual for a beta carbon in 
an -unsaturated system, with -unsaturated cyclohexanone only reaching 150.6 ppm.107 
The deshielded resonance indicates ring strain in the trans-decalin structure. This is presumably 
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why in the first attempt at structure elucidation, it was noticed that the compound was 
decomposing. The solvent, MeOH, could undergo a Michael addition to the -unsaturated 
ketone. 
 
Figure 5.3 Key HMBC Correlations of 5.6 
Table 5.2: NMR Spectroscopic Data (500 MHz, CDCl3) for 2-oxoavarol (5.6) 
    2-oxoavarol (6)   
position C
a
 
 type H, (J in Hz)
b COSY
b 
HMBC
b
 (
1
H to 
13
C) 
1a 36.6  CH 2.39, d (12.1) H-10 C-2, C-10 
2 202.4
c
  qC    
3 125.5 CH 5.63, d (1.2) H-15 C-5, C-15 
4 173.0
c
 qC    
5 40.2
c
 qC    
6 34.7 CH2 1.69, m  C-10 
7a 27.0 CH2 1.45, m   
7b   1.45, m   
8 35.3 CH 1.57, m H-13  
9 41.3
c
 qC    
10 45.9 CH 1.71, d (12.1) H-1 C-1, C-5, C-9, C-12,  
11a 37.0  CH2 2.77, d (14.3) H-11b C-8, C-9, C-16, C-17, C-21 
11b   2.43, d (14.3) H-11a C-9, C-10, C-16, C-17, C-21 
12 17.6  CH3 0.91, s  C-8, C-9, C-10, C-11,  
13 17.2 CH3 1.04, d (6.8) H-8 C-7, C-8, C-9 
14 18.1 CH3 1.15, s   C-4, C-5, C-6, C10 
15 19.0 CH3 1.79, d (1.2) H-3 C-3, C-4, C-5 
16 125.6
c
 qC    
17 148.6
c
 qC    
18 116.2 CH 6.56, m  C-16, C-20 
19 113.9 CH 6.55, m  C-21 
20 148.7
c
 qC    
21 119.4  CH 6.53, br d (1.5)  C-11, C-17, C-19 
a
Carbon spectra recorded at 125 MHz. 
b
Proton spectra recorded at 500 MHz. 
c
Carbons acquired through HMBC 
correlations. 
 
5.1.2.  Relative and Absolute Configuration of 5.5-5.6 
Relative configuration of 5.5 was determined through J based analyses and NOE correlations. 
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Both methines H-3 and H-10 displayed a large J of 12 Hz which placed them both axial in a 
cyclohexane system. An NOE between H-14 and H-3 indicated they were cis. Additional NOE 
was observed between H-12 to H-13 and H-14 placed these methyl groups cis to H-3. Absolute 
configuration could not be determined due to insufficient material. Absolute or relative 
configuration of 5.6 could not be determined due to degradation of the material when conducting 
2D NMR experiments. 
 
Figure 5.4 Relative Configuration of 5.5. Key NOE (Black arrows) and coupling constant values used in the determination of 
5.5’s relative configuration. 
5.2. Bioactivity of 5.5-5.6 
Although preliminary data on this family of compounds displayed weak inhibition of BACE1, 
IC50’s on these compounds could not be determined due to the in-house assay system being 
discontinued and the eventual degradation of material. However, a very similar compound, 
ilimaquinone, was determined to inhibit BACE1 with an IC50 of 65 µM. Therefore, it is likely 
that new compounds 5.5 and 5.6 would also show a low degree of BACE1 inhibition. 
 
Figure 5.5 Ilimaquinone. 
 
41 
 
5.3. Comments on 5.5-5.6 
Biosynthetically, farnesyl pyrophosphate is presumed to be the precursor for the decalin 
ring.
108
 Electrophilic attack at the head position of the farnesyl derivative initiates a cyclization 
to create a bicyclic carbocation intermediate. A series of 1,2-hydride and alkyl shifts result in the 
rearranged friedodrimane structure while removal of a proton quenches the cation, generating the 
resultant olefin. Alternatively, intramolecular nucleophilic attack can also occur on the 
rearranged cation to yield many other previously isolated drimanes including puupehenol,
109
 ent-
chromazonarol,
110
 and aureol.
111
  This suggests it is likely that the hydroquinone or quinone is 
added before the decalin ring gets assembled. 
  
Figure 5.6 Likely Formation of Drimane and Friedodrimane Compounds. A) General formation of drimanes and rearranged 
friedodrimane skeletons. B) Plausaible biosynthesis of 5.5. C) Known compounds arising from the intramolecular 
quenching via attack of the hydroquinone. 
Compound 5.5, could arise through the same steps if the olefin at the head position was first 
subjected to an epoxidation before electrophilic attack and cyclization. To the author’s 
knowledge, 5.5 is the first friedodrimane and only the third drimane to be oxygenated on the A 
ring (the other two being 3-ketotauranin and 3-hydroxytauranin). Compound 5.6 is unusual due 
to its oxidation at position 2 and has no obvious biogenesis. 
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Figure 5.7 3-Ketotautanin and 3α-Hydroxytauranin. 
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CHAPTER 6 
6.  Experimental 
6.1. General Experimental Conditions 
6.1.1. NMR 
1
H, 
13
C NMR and 2D NMR experiments on the natural products were carried out on Varian 
Unity Inova 500 MHz spectrometer. NMR spectra were referenced to the appropriate residual 
solvent signal (δH 7.26, δC 77.2 for CDCl3; δH 3.30, δC 49.0 for MeOH-d4) with chemical shifts 
reported in δ units (ppm). Multiplicities are as indicated in the list of abbreviations. The HSQC 
experiments were optimized for 
1
JC,H = 140 Hz and HMBC experiments for 
3
JC,H = 7 Hz. Mixing 
times for ROESY and NOESY experiments were 500 ms and generally 80 ms for the 1D TOCSY 
experiments. 
 
6.1.2. Mass Spectrometry 
High-resolution ESI mass spectra were recorded in the positive or negative mode on an Agilent 
1100 LC coupled to an Agilent 6210 MSD-TOF.  The gas temperature was held at 325 °C, sheath 
nitrogen flow rate was set at 10 L/min, and the nebulizer at 30 psig.  The ESI source needle 
voltage was set at 3.5 kV.  For compounds 3.1 and 3.2, the APCI source was used with the 
voltage set at 3.5 kV. Low-resolution ESI mass spectra were recorded in the positive/negative 
mode by an Agilent 1200 LC coupled to an Agilent 6410 Triple Quad MS.  In these cases, the 
gas temperature was held at 325 °C, sheath nitrogen flow rate was set at 10 L/min, and the 
nebulizer at 30 psig. The ESI source needle voltage was set at 3.5 kV.  
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6.1.3.  IR, UV, CD, and Optical Rotations 
The UV spectra were determined on a Varian Cary 50 Bio series spectrophotometer and the IR 
spectra were recorded on a Shimadzu IRAffinity-1 series FTIR instrument as a thin solid on 
either CaF2 or NaCl disks. CD spectrum was measured on a Jasco J-815 CD spectrometer with 
the sample dissolved in MeOH.  The optical rotations were measured on a Jasco-DIP-700 
polarimeter at the sodium D line (589 nm).  
6.1.4. Computational Analysis 
Conformers within 5 kcal/mol of the lowest energy conformer were searched using the Monte 
Carlo multiple minimum (MCMM) method and the OPLS-2005 force field in MacroModel 
(Schrodinger Inc.). Each conformer within 5 kcal/mol of the lowest energy conformer was 
optimized in Gaussian09
112
 at the M06-2X/6-31+G level and the geometries of all conformers 
with similar energies were checked for redundancy. Density functional theory (DFT) was used to 
perform calculations, which were carried out in Gaussian 09. All ground-state geometries were 
optimized at the B3LYP/6-31+G level. The same DFT level was employed to evaluate the 
effects of solvation in methanol using the SCRF/PCM method.
113,114
  TDDFT
88,89 
calculations at 
the B3LYP/6-31+G and the B3LYP/aug-cc-pVDZ levels were conducted to calculate the 
electronic excitation energies and rotational strengths in methanol. 
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6.2. Biological Material 
6.2.1. Extraction and Isolation of Metabolites from Hexabranchus 
sanguineus 
The egg masses of Hexabranchus sanguineus were collected via SCUBA off the west shore of 
O’ahu at Electric Beach (21°21'14.3"N 158°07'49.7"W) at a depth of 20 feet on September 23rd, 
2011. The two egg masses collected were bright pink and were immediately extracted with 1:1 
MeOH:CH2Cl2 three times overnight to yield 2.7 g of extract. The combined extract was then dry 
loaded on C8 silica gel and was subjected to a solid phase extraction procedure consisting of five 
steps of increasing MeOH:H2O content (0%, 25%, 50%, 75%, 100%, and an isopropanol wash). 
The 75% MeOH fraction was subjected to reversed-phase HPLC on a Phenomenex column 
(Luna C8; 250x10 mm, 5 µ) using a flow rate of 2.8 mL/min and a concentration gradient of 
50%-70% (CH3CN:H2O) over 30 min. Detection was by UV, using a PDA and monitoring at 
249 nm. This afforded pure compounds ulapualide B (2.2, tR = 24 min, 8 mg, 0.32% yield), 
ulapualide A (2.1, tR = 21 min, 6 mg, 0.24% yield; [α]
22
D  -39, c 0.20, MeOH), ulapualide C (2.3, 
tR = 18.5 min, 1.6 mg, 0.064% yield) and a mixture of ulapualides D and E. This mixture was 
further purified using a C18 column (Luna; 100x4.6 mm, 5 µ) at a flow of 1.0 mL/min and using 
an isocratic system of 65% MeOH-H2O to yield ulapualide D (2.4, tR =20 min, 0.5 mg, 0.02% 
yield) and ulapualide E (2.5, tR =24 min, 0.5 mg, 0.02% yield). Purity was assessed at 210 nm 
and determined to be 95.3%, 94.5%, and 95.6% for 2.1, 2.2 and 2.3 respectively, prior to 
biological testing. 2.4 and 2.5 were 91% and 85%  pure by NMR respectively. 
6.2.2. Extraction and Isolation of Metabolites from Callyspongia sp. 
The pink and lavender sponge belonging to the genus Callyspongia (class Demospongiae, 
46 
 
order Haplosclerida, family Callyspongiidae) was collected at Black Rock, Maui (20°55'36.8"N, 
156°41'47.8"W) at a depth of 28 ft. The sponges turned brown above water and were extracted 
with 1:1 MeOH:CH2Cl2 three times overnight to yield 1.7 g of extract. The combined extract was 
dissolved in MeOH and subject to a modified Kupchan partitioning with Hex, CH2Cl2, and H2O. 
The CH2Cl2 partition (451 mg) was dry loaded on C8 silica gel and underwent a solid phase 
extraction procedure consisting of five steps of increasing MeOH:H2O content (0%, 25%, 50%, 
75%, 100%, and an isopropanol wash). The 75% MeOH fraction (62 mg) was subjected to 
reversed-phase HPLC on a Phenomenex column (Luna C18; 150x4.6 mm, 5 µ) using a flow rate 
of 1.0 mL/min and a concentration gradient of 50%-100% (MeCN:H2O) over 20 min and then 
holding at 100% MeCN for an additional 10 min. This afforded known callyspongynic acid (3.1, 
tR = 4.5 min, 6 mg, 0.4% yield), and small quantities of decarboxycallyspongynic acid.  HPLC of 
the 100% MeOH fraction using the same method afforded larger quantities of 
decarboxycallyspongynic acid (3.2, tR = 23.7 min, 0.6 mg, 0.04% yield). Purity was assessed by 
NMR and 3.1 and 3.2 were deemed to be 92% and 94% pure respectively. 
6.2.3.  Extraction and Isolation of Metabolites from Myrmekioderma. 
450 grams of an undescribed species of Myrmekioderma (class Demospongiae, order 
Axinellida, family Heteroxyiidae) was collected 40-60 ft. deep off the southern shore of Lana’i at 
second cathedral (roughly 20°44'05.0"N, 156°55'25.7"W). The encrusting sponge has fingery 
projections and a smooth surface, produces clear mucus, cream colored in life and in spirit, and 
the interior has a pulpy consistency. The ectosomal skeleton is parchment-like and readily 
detachable, it consists of a tangential layer of a smaller category of strongyles (~265 x 9.8 µm). 
The choanosomal skeleton is largely confused with ascending tracts of larger strongyles (~555 x 
9.5µm) among disorganized spicules including fine oxea/strongyles (~325 x 2.5µm) and 
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abundant rhaphides in 2 sizes of trichodragmata (~52.5 and 80µm). All megascleres are smooth, 
centrally curved or occasionally flexuous. 
 100 g of lyophilized sponge was extracted with 1:1 MeOH:CH2Cl2 three times overnight to 
yield 5.77 g of crude extract. The combined extract was then subjected to a modified Kupchan 
partitioning using only MeOH, Hex, and CH2Cl2. The CH2Cl2 partition (177.5 mg) was dry 
loaded on C8 silica gel and was subjected to a solid phase extraction procedure consisting of five 
steps of increasing MeOH:H2O content (0%, 25%, 50%, 75%, 100%, and an isopropanol wash).  
Both the 50% MeOH and the 75% MeOH fractions contained our compounds of interest. The 
50% was subjected to reversed phase HPLC on a Phenomenex column (Luna C18; 250x10 mm, 
5 µ) using a flow rate of 2.8 mL/min and a concentration gradient of 40%-80% (ACN:H2O) over 
20 min. This afforded pure compounds 4.1 (tR = 15.8 min, 0.6 mg, 0.01% yield) and 4.2 (tR = 
16.1 min, 1 mg, 0.02% yield), and mixtures 4.3 (tR = 8 min, 2.3 mg, 0.04% yield) and 4.4 (tR = 9 
min, 2.2 mg, 0.04% yield). Purity was assessed by NMR  and determined to be 95%, 88%, 85% 
and 77% for 4.1, 4.2, 4.3, and 4.4, respectively.  
6.2.4. Extraction and Isolation of Metabolites from an Unidentified 
Hawaiian Sponge 
The white, cobweb-like sponge was collected at Kewalo pipe, Oahu (21°17'25.6"N 
157°51'47.3"W) at a depth of 15 ft. 60 g of lyopholized sponge was extracted with 1:1 
MeOH:DCM three times overnight to yield 5.98 g of crude extract. The combined extract was 
then subjected to a solid phase extraction over 180 g of C8 silica gel with the eluents 25% 
MeOH:H2O, MeCN, 100% MeOH, and CH2Cl2. The MeCN fraction, 876 mg, was subjected to 
reversed phase, flash column chromatography with a gradient of 50% MeOH:H2O to 100% 
MeOH to yield 4 fractions (pink, orange, green, and purple). The second (orange) fraction was 
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subjected to preparative HPLC of on a Phenomenex column (Gemini C18; 250x21.2 mm, 5 µ) 
with a gradient of 80%-100% (ACN:H2O) over 20 min at flow rate of 10 mL/min. This afforded 
a mixture of 5.1 and 5.2 (tR = 14.0 min), 5.3 (tR = 19.5 min), and impure 5.4 (tR = 23.7 min). 5.1 
and 5.2 were further separated on a Sepulco column (Pentaflourophenyl; 250x4.6 mm, 5 µ) using 
a flow rate of 1.0 mL/min and a concentration gradient of 70%-75% (MeOH:H2O) over 20 min 
and injecting 50 µg.  The pink fraction was subjected to reversed phase HPLC on a Phenomenex 
column (Luna C18; 250x10 mm, 5 µ) using a flow rate of 2.8 mL/min and a concentration 
gradient of 30%-100% (ACN:H2O) over 20 min to yield a mixture of 5.5 and 5.6 (tR = 20.7 min). 
Further HPLC on a Phenomenex column (Luna Si; 150x4.6 mm, 5 µ) using a flow rate of 2.0 
mL/min isocratically at 35% EtOAC:Hex  to afford pure 5.5 (tR = 6.6 min, 1 mg, 0.02% yield) 
and 5.6 (tR = 4.4 min, 0.8 mg, 0.01% yield). Purity was assessed by NMR and were deemed 
81%, 83%, 85%, 70% pure for known compounds 5.1, 5.2, 5.3 and 5.4, respectively. Compounds 
5.5 and 5.6 were both determined to be 95% pure by NMR. 
 
6.3. Assay Protocols 
6.3.1.  BACE1 Assays 
The HitHunter BACE1 EFC chemiluminescence assay was purchased from DiscoveRx and 
was run in house.  The proteolytic cleavage of amyloid precursor protein was assayed as 
described by Naqvi
115
. Test compounds were solubilized in DMSO at the desired concentration 
and incubated in triplicate with the enzyme for 16 h in 96-well plates. A DMSO control (1.5 μL) 
and an inhibitor standard were also tested in triplicate. The chemiluminescence signal was read 
using a Fluostar Optima spectrophotometer. Data were analyzed using GraphPad Prism. BACE1 
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activity was calculated as a percent of the positive control using a nonlinear regression analysis 
function that corresponded to a best one-fit model. 
The BACE1 Affinity assay was run in house. 50 µL of a 0.1 µg/µL BACE1 enzyme solution in 
a buffer consisting of 80% 10mm NH4HCO3 and 20% LC-MS grade MeOH was incubated 
overnight with 10 µL of a 5 µg/µL MeOH solution of extract and 10 µL of a 0.005 µg/µL MeOH 
solution of BACE1 inhibitor IV (Calbiochem). Bio-Gel P-6 Gel (150mg) was placed in a plastic 
Bio-Spin column and was equilibrated with 1:4 MeOH:buffer solution. Enzyme-extract-inhibitor 
solution (20 µL) was added to the column and centrifuged for 1 min at 4C and 1000 rcf. The 
solution in the receiving vessel was transferred to the insert in the LC-MS vial and LC-ESI-
TOFMS was performed separating over a Luna C18 150 x 4.6 mm column with particle size 3 
microns. A positive control of just the extract, a negative control of the extract spun down on the 
SEC only, and the experiment of the above described process was run for every sample. 
6.3.2.  Cytotoxicity Assays  
Human renal cell adenocarcinoma (768-0), prostate carcinoma (DU-145), mammary gland 
adenocarcinoma (MDA-MB-231) and lung carcinoma (A549) cell lines were maintained in 
RPME 1640 Medium (Gibco, REF: 11875-093) supplemented with 10% premium fetal bovine 
serum (Atlanta biological, Cat. No.: S11150) and 100 U/mL penicillin and 100 µg/mL 
streptomycin (Gibco, REF: 15140-122). The day before treatment, cancer cells were seeded with 
4,000 cells per well into a 96-well tissue culture plate. Twenty hours post seeding, the serial 
diluted compounds were added to the cells for the cytotoxicity assay, and co-incubated at 37 
o
C 
with 5% CO2 for 72 h. Then the medium with compounds were replaced with 1 × dye binding 
solution prepared according to the manufacturer’s instruction (CyQuant NF Cell Proliferation 
Assay Kit [C35006, Invitrogen]) and incubated at 37 
o
C with 5% CO2 for 60 minutes. After that, 
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cell viability data were collected with a PerkinElmer Multimode Plate Reader according to the 
manufacturer’s instruction. IC50 curves were generated using GraphPad Prism 5. 
Human panc-1 cell lines were maintained in DMEM media supplemented with 10% premium 
fetal bovine serum and 50 U/mL penicillin and 50 µg/mL streptomycin. The day before 
treatment, cancer cells were seeded with 5,000 cells per well into a 96-well tissue culture plate. 
Twenty-four hours post seeding, the serial diluted compounds were added to the cells making 
total volume of the cell mixture to 200 uL for the cytotoxicity assay, and incubated at 37 
o
C with 
5% CO2 for 72 h. Then 40 uL MTS dye (CellTiter aqueous One Solution Cell Proliferation 
Assay) was added to each well and incubated at 37 
o
C with 5% CO2 for 90 minutes. After that, 
cell viability data were collected with a Modulus Microplate Reader. IC50 curves were generated 
using GraphPad Prism 5. 
 
6.3.3.  ER-alpha Assay 
Assay was conducted through ThermoFischer Scientific’s SelectScreen™ biochemical nuclear 
receptor profiling service employing the LanthaScreen™ TR-FRET Coregulator assay and using 
17--estradiol as the stimulant.  
 
6.4. Physical Data 
 
Ulapualide A (2.1): [α]22D  -39, c 0.20, MeOH; all other spectroscopy data was found to be 
identical to literature values.
38
 Notebook SP-I-89 
Ulapualide B (2.2): spectroscopy data was found to be identical to literature values.
38
 Notebook 
SP-I-89 
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Ulapualide C (2.3): white amorphous powder; [α]22D  -17 (c 0.32, MeOH); UV (MeOH) λmax (log 
ε) 249 (4.5), 237 (4.6), 202 (4.5); IR νmax 3600-3200 (br), 3162, 2964, 2934, 1720, 1691, 1655, 
1597, 1458, 1241, 1086, 916 cm
-1
. Tables 2.1 and 2.2 for NMR data; HRESI-TOFMS m/z 
883.4700 [M+H]
+
 (calcd for C46H67N4O13, 883.4705). Notebook SP-I-89 
Ulapualide D (2.4): white amorphous powder; [α]22D  -10 (c 0.08, MeOH); UV (MeOH) λmax 
(log ε) 249 (4), 213 (5), 202 (5); Tables 2.1 and 2.2 for NMR data; HRESI-TOFMS m/z 
883.4662 [M+H]
+
 (calcd for C46H67N4O13, 883.4705). Notebook SP-I-89 
Ulapualide E (2.5): white amorphous powder; [α]22D  -23 (c 0.10, MeOH); UV (MeOH) λmax (log 
ε) 249 (4), 213 (5), 202 (5); Tables 2.1 and 2.2 for NMR data; HRESI-TOFMS m/z 985.4976 
[M+H]
+
 (calcd for C50H73N4O16, 985.5022). Notebook SP-I-89 
Callyspongynic Acid (3.1): [α]22D  -4.0, c 0.50, EtOH; all other spectroscopy data was found to 
be identical to literature values.
74
 Notebook SP-II-58 
Decarboxycallyspongynic acid (3.2): white amorphous powder; [α]22D  -9.8 (c 0.5, EtOH); UV 
(MeOH) λmax (log ε) 202 (4.3), 214 (4.1); IR νmax (CaF2) 3413, 3295, 2115, 1589; See Table 1 
For NMR Data;  HRESI-TOFMS m/z 427.3010 [M+H]
+
 (calcd for C31H39O, 427.2995). 
Notebook SP-II-58 
Myrmenaphthol A (4.1): yellow amorphous powder; [α]22D  -79 (c 0.2, MeOH); UV (MeOH) λmax 
(log ε) 362 (3.8), 240 (4.1), 203 (4.2) nm; IR (CaF2) νmax 3396, 1667, 1597, 1218 cm
-1
; See Table 
4.1 for NMR data; HRESI-TOFMS m/z 307.1335 [M+H]
+
 (calcd for C20H19O3, 307.1329). 
Notebook SP-II-75 
Cinanthrenol A (4.2): spectroscopy data was found to be identical to literature values.
86
 
Notebook SP-II-75 
3,4-Dihydroxypregna-5,17-diene-10,2-carbolactone (4.3): spectroscopy data was found to be 
identical to literature values.
83
 Notebook SP-II-75 
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3,4-dihydroxypregna-5,20-diene-10,2-carbolactone (4.4): spectroscopy data was found to be 
identical to literature values.
83
 Notebook SP-II-75 
Avarol (5.1): spectroscopy data was found to be identical to literature values.
94
 Notebook SP-II-
27-31 
Isoavarol (5.2): spectroscopy data was found to be identical to literature values.
116
 Notebook SP-
II-27-31 
Avarol monoacetate (5.3): all spectroscopy data was found to be identical to literature values.
117
 
Notebook SP-II-27-31 
Avarone (5.4): Compound was collected as a mixture, 
1
H NMR and HRMS data was found to be 
identical to literature values.
94
 Notebook SP-II-27-31 
3-Hydroxyisoavarol (5.5): white amorphous powder; [α]22D  0.8 (c 0.2, CHCl3); UV (MeOH) 
λmax (log ε) 243 (3.06); See Tables 5.1 for NMR data; HRESI-TOFMS m/z 329.2095 [M+H]
+
 
(calcd for C21H29O3, 329.2111). Notebook SP-II-27-31 
2-Oxoavarol (5.6): white amorphous powder; optical rotation and UV data were not collected 
due to decomposition; See Table 5.2 for NMR data; HRESI-TOFMS m/z 327.1946 [M+H]
+
 
(calcd for C21H27O3, 327.1955). Notebook SP-II-27-31 
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Appendix 1:  
1
H NMR Spectrum of Ulapualide A (2.1) (CDCl3, 500 MHz) 
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Appendix 2:  
13
C NMR Spectrum of Ulapualide A (2.1) (CDCl3, 125 MHz) 
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Appendix 3:  
1
H NMR Spectrum of Ulapualide B (2.2) (CDCl3, 500 MHz) 
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Appendix 4:  
13
C NMR Spectrum of Ulapualide B (2.2) (CDCl3, 125 MHz) 
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Appendix 5:  
1
H NMR Spectrum of Ulapualide C (2.3) (CDCl3, 500 MHz) 
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Appendix 6:  
13
C NMR Spectrum of Ulapualide C (2.3) (CDCl3, 125 MHz)  
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Appendix 7:  gHSQC Spectrum of Ulapualide C (2.3) (CDCl3, 500 MHz) 
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Appendix 8:  gCOSY Spectrum of Ulapualide C (2.3) (CDCl3, 500 MHz) 
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Appendix 9:  gHMBC Spectrum of Ulapualide C (2.3) (CDCl3, 500 MHz) 
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Appendix 10:  
1
H NMR Spectrum of Ulapualide D (2.4) (CDCl3, 500 MHz)  
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Appendix 11:  
13
C NMR Spectrum of Ulapualide D (2.4) (CDCl3, 125 MHz) 
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Appendix 12:  gHSQC Spectrum of Ulapualide D (2.4) (CDCl3, 500 MHz) 
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Appendix 13:  gCOSY Spectrum of Ulapualide D (2.4) (CDCl3, 500 MHz) 
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Appendix 14:  HMBC Spectrum of Ulapualide D (2.4) (CDCl3, 500 MHz) 
  
72 
 
Appendix 15:  
1
H NMR Spectrum of Ulapualide E (2.5) (CDCl3, 500 MHz)  
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Appendix 16:  
13
C NMR Spectrum of Ulapualide E (2.5) (CDCl3, 125 MHz) 
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Appendix 17:  gHSQC Spectrum of Ulapualide E (2.5) (CDCl3, 500 MHz) 
 
  
75 
 
Appendix 18:  gCOSY Spectrum of Ulapualide E (2.5) (CDCl3, 500 MHz) 
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Appendix19:  HMBC Spectrum of Ulapualide E (2.5) (CDCl3, 500 MHz) 
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Appendix 20:  IC50 Curves for Ulapualides A-C (2.1-2.3) Against Select Cell Lines 
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Appendix 21:  Image of Hexabranchus sanguineus Egg Mass 
 
Collected approximately 20 ft deep at Electric Beach, O’ahu (21°21'14.3"N 158°07'49.7"W). 
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Appendix 22:  
13
C Chemical Shifts of Minor Rotamers of Ulapualides A-C (1-3) (CDCl3, 125 MHz) 
 
  1  2  3  
position  C type  C  type  C type 
26-OMe     57.8 CH3     
27     34.5 CH     
29  39.5 CH2  30.2 CH2     
30  211.7 C     69.9 CH  
31  48.8 CH  37.3 CH     
31-Me     9.6 CH3  8.4 CH3  
32-OAc        172.47
a 
C  
32-OAc        20.8 CH3  
33  36.9 CH  37.0 CH      
33-Me     19.4 CH3     
34  112.1 CH  112.0 CH  112.0 CH  
35  125.4 CH  125.4 CH  125.4 CH  
35-NMe  33.0 CH3  33.0 CH3  33.0 CH3  
35-NCHO  160.9 CH  160.9 CH  160.8 CH  
36     170.3 C     
a
The minor rotamer for 32-OAc is the more shielded of the two resonances at δC 172.5  
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Appendix 23:  
1
H NMR Spectrum of Callyspongynic Acid (3.1) (CD3OD, 500 MHz) 
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Appendix 24:  
13
C NMR Spectrum of Callyspongynic Acid (3.1) (CDCl3, 125 MHz)  
 
 
82 
 
Appendix 25:  
1
H NMR Spectrum of Decarboxycallyspongynic Acid (3.2) (CD3OD, 500 MHz) 
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Appendix 26:  
13
C NMR Spectrum of Decarboxycallyspongynic Acid (3.2) (CD3OD, 125 MHz) 
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Appendix 27:  gHSQC Spectrum of Decarboxycallyspongynic Acid (3.2) (CD3OD, 500 MHz) 
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Appendix 28:  gDQCOSY Spectrum of Decarboxycallyspongynic Acid (3.2) (CD3OD, 500 MHz) 
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Appendix 29:  gHMBC Spectrum of Decarboxycallyspongynic Acid (3.2) (CD3OD, 500 MHz) 
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Appendix 30:  Image of Callyspongia sp. 
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Appendix 31:  
1
H NMR Spectrum of Myrmenaphthol A (4.1) (CD3OD, 500 MHz)  
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Appendix 32:  
13
C NMR Spectrum of Myrmenaphthol A (4.1) (CD3OD, 125 MHz) 
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Appendix 33:  gHSQC Spectrum of Myrmenaphthol A (4.1) (CD3OD, 500 MHz)  
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Appendix 34:  gDQCOSY Spectrum of Myrmenaphthol A (4.1) (CD3OD, 500 MHz) 
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Appendix 35:  gHMBC Spectrum of Myrmenaphthol A (4.1) (CD3OD, 500 MHz) 
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Appendix 36:  ROESY Spectrum of Myrmenaphthol A (4.1) (CD3OD, 500 MHz)  
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Appendix 37:  
1
H NMR Spectrum of Cinanthrenol A (4.2) (CD3OD, 500 MHz)  
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Appendix 38:  gHSQC Spectrum of Cinanthrenol A (4.2) (CD3OD, 500 MHz) 
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Appendix 39:  gHMBC Spectrum of Cinanthrenol A (4.2) (CD3OD, 500 MHz) 
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Appendix 40:  Image of Myrmekioderma sp. 
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Appendix 41:  
1
H NMR Spectrum of Impure 3,4-dihydroxypregna-5,17-diene-10,2-carbolactone (4.3) (CD3OD, 500 MHz) 
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Appendix 42:  
1
H NMR Spectrum of 3,4-dihydroxypregna-5,20-diene-10,2-carbolactone (4.4) (CD3OD, 500 MHz)  
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Appendix 43:  
1
H NMR Spectrum of Avarol (5.1) (CD3OD, 500 MHz)  
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Appendix 44:  
13
C NMR Spectrum of Avarol (5.1) (CD3OD, 125 MHz) 
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Appendix 45:  
1
H NMR Spectrum of Isoavarol (5.2) (CD3OD, 500 MHz)  
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 Appendix 46:  
13
C NMR Spectrum of Isoavarol (5.2) (CD3OD, 125 MHz) 
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Appendix 47:  
1
H NMR Spectrum of Avarol Monoacetate (5.3) (CDCl3, 500 MHz)  
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 Appendix 48:  
13
C NMR Spectrum of Avarol Monoacetate (5.3) (CDCl3, 125 MHz)  
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Appendix 49:  
1
H NMR Spectrum of Avarone (5.4) (CDCl3, 500 MHz)  
 
  
107 
 
Appendix 50:  
1
H NMR Spectrum of 3-hydroxyisoavarol (5.5) (CD3OD, 500 MHz)  
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 Appendix 51:  
13
C NMR Spectrum of 3-hydroxyisoavarol (5.5) (CD3OD, 125 MHz) 
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Appendix 52:  gHSQC Spectrum of 3-hydroxyisoavarol (5.5) (CD3OD, 500 MHz)  
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Appendix 53:  gDQCOSY Spectrum of 3-hydroxyisoavarol (5.5) (CD3OD, 500 MHz) 
 
  
111 
 
Appendix 54:  gHMBC Spectrum of 3-hydroxyisoavarol (5.5) (CD3OD, 500 MHz)  
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Appendix 55:  NOE Spectrum of 3-hydroxyisoavarol (5.5) Irradiated at δH 0.84 ppm (CD3OD, 500 MHz)  
 
  
113 
 
Appendix 56:  NOE Spectrum of 3-hydroxyisoavarol (5.5) Irradiated at δH 1.05 ppm (CD3OD, 500 MHz)  
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 Appendix 57:  
1
H NMR Spectrum of 2-oxoavarol (5.6) (CD3OD, 500 MHz)  
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Appendix 58:  
13
C NMR Spectrum of 2-oxoavarol (5.6) (CD3OD, 125 MHz) 
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Appendix 59:  
1
H NMR Spectrum of 2-oxoavarol (5.6) (CD3OD, 500 MHz) 
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Appendix 60:  
1
H NMR Spectrum of 2-oxoavarol (5.6) (CDCl3, 500 MHz) (Presat at 1.57 ppm) 
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Appendix 61:  gDQCOSY Spectrum of 2-oxoavarol (5.6) (CDCl3, 500 MHz) 
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Appendix 62:  gHSQC Spectrum of 2-oxoavarol (5.6) (CD3OD, 500 MHz)  
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Appendix 63:  gHMBC Spectrum of 2-oxoavarol (5.6) (CD3OD, 500 MHz) 
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Appendix 64:  Image of Unidentified Hawaiian Sponge 
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